Corbus制药公司 Q2 EPS超出预期,分析师调整了价格目标。 Corbus Pharmaceuticals Q2 EPS exceeded expectations and analysts adjusted price targets.
Wedbush将Corbus制药公司的价格目标从85美元降至51美元,而Oppenheimer将其目标从80美元提高到88美元。 Wedbush reduced its price target for Corbus Pharmaceuticals (CRBP) from $85 to $51, while Oppenheimer raised its target from $80 to $88. CRBP报告说,Q2 EPS损失0.90美元,超过预期的1.19美元。 CRBP reported a Q2 EPS loss of $0.90, exceeding expectations of $1.19. 平均目标价格为65.86美元,中度购买评级。 The average target price is $65.86, with a moderate buy rating. Corbus侧重于发展癌症治疗,包括CRB-701、CRB-601和CRB-913。 Corbus focuses on developing cancer treatments, including CRB-701, CRB-601, and CRB-913. 该公司的市场上限为2.085亿美元,P/E比率为-2.80。 The company's market cap is $208.5 million, with a P/E ratio of -2.80.